Sintilimab Plus Bevacizumab Biosimilar Versus Sorafenib as First-Line Treatment for Unresectable Hepatocellular Carcinoma: A Cost-Effectiveness Analysis

Objective: The ORIENT-32 clinical trial revealed that sintilimab plus bevacizumab biosimilar significantly improved the median progression-free survival and median overall survival (OS) compared with sorafenib. This analysis evaluated the cost-effectiveness of sintilimab plus bevacizumab biosimilar...

Descripción completa

Detalles Bibliográficos
Autores principales: Peng, Ye, Zeng, Xiaohui, Peng, Liubao, Liu, Qiao, Yi, Lidan, Luo, Xia, Li, Sini, Wang, Liting, Qin, Shuxia, Wan, Xiaomin, Tan, Chongqing
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2022
Materias:
Pharmacology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8864224/
https://www.ncbi.nlm.nih.gov/pubmed/35222020
http://dx.doi.org/10.3389/fphar.2022.778505

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8864224/
https://www.ncbi.nlm.nih.gov/pubmed/35222020
http://dx.doi.org/10.3389/fphar.2022.778505

Ejemplares similares